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Background. Little is known about the antibody response in natural infection by the novel 2009 influenza A
(H1N1) virus and its relationship with clinical and virological parameters. The relative lack of background neu-
tralizing antibody against this novel virus provides a unique opportunity for understanding this issue.
Methods. Case patients presenting with influenza-like illness who were positive for the pandemic H1 gene by
reverse transcription polymerase chain reaction were identified. The serum antibody response was assayed by
neutralizing antibody titer (NAT) against the virus in 881 convalescent donors. We retrospectively analyzed clinical
parameters and viral load.
Results. Ninety percent of the 881 convalescent donors had seroprotective titer of 1:40 or greater. The geometric
mean titer of donors with convalescent NAT measured between day 21 and 42 was 1:101.1. Multivariate analysis
by ordinal regression showed that pneumonia (odds ratio, 3.39; 95% confidence interval, 1.49–7.61; )Pp .004
and sputum production (odds ratio, 1.75; 95% CI, 1.01–3.01; ) were the 2 independent factors associatedPp .046
with a higher level of convalescent NAT. Being afebrile on influenza presentation was associated with subsequent
poor NAT (!1:40) response ( ). A positive correlation between the nasopharyngeal viral load on presentationPp .04
and the convalescent NAT was demonstrated (Spearman correlation r, 0.238; ).Pp .026
Conclusions. About 10% of these convalescent patients do not have a seroprotective NAT and may benefit
from vaccination to prevent reinfection. The convalescent NAT correlated well with the initial viral load and was
independently associated with severity of the viral illness, including pneumonia. The findings provide both the
clinical and virological markers for identifying potential convalescent plasma donors with high serum NAT, which
can be used to produce hyperimmune intravenous immunoglobulin in a randomized treatment trial for patients
with severe pandemic H1N1 infection.
Since the emergence of the novel 2009 influenza A
(H1N1) virus in March 2009, the virus has caused a
pandemic affecting 1213 countries, with at least 17,700
deaths [1]. In Hong Kong, the number of laboratory-
confirmed cases has exceeded 30,000, resulting in 150
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deaths [2]. Although oseltamivir appeared to be useful
if instituted within 48 h of onset of symptom in mild
cases, the viral load and clinical outcome in severe cases
with respiratory failure, especially those who presented
late, did not respond well to antiviral therapy [3]. Thus,
other modalities of therapy including intravenous neur-
aminidase inhibitors [4, 5] and convalescent plasma or
intravenous immunoglobulin with high neutralizing
antibody titer (NAT) are investigated as salvage therapy
for this particular group of patients. Because premar-
keting trials with the monovalent 2009 influenza A
(H1N1) vaccine demonstrated good NAT after a single
dose of 15 mg hemagglutinin given to adults [6–8], a
mass vaccination program has commenced in most de-
 at University of Hong Kong on January 18, 2011
cid.oxfordjournals.org
D
ow
nloaded from
 
Neutralizing Antibody against H1N1 • CID 2010:51 (1 August) • 275
veloped areas [9], including Hong Kong, which started in late
December 2009. This offers protection to at-risk individuals
with pregnancy, chronic illness, or extremes of age against the
infection. Unlike vaccination studies, parameters affecting the
level of neutralizing antibody after natural influenza infection
are quite unknown. The difficulty of getting such data lies
mainly with repeated exposure to different strains of antigen-
ically drifted influenza A virus. Nevertheless, recent studies have
demonstrated that most patients born after 1950 have no pre-
existing crossreactive antibodies against this novel virus [10].
This provided us with a unique opportunity to investigate the
parameters which can affect the specific NAT in individuals
aged !60 years, who have recovered from the virologically doc-
umented infection before the vaccination program began. Find-
ings will improve our understanding of the seroepidemiology
for vaccination strategy and facilitate the identification of po-
tential donors for convalescent plasma with higher NAT [11],
which may be suitable for production of hyperimmune intra-
venous immunoglobulin. Such a product can be tested in a
randomized control treatment trial for severe cases of infection.
METHODS
This study was approved by the institutional review board of
the Hospital Authority of Hong Kong. From 1 September
through 30 October 2009, patients aged !60 years who have
recovered from 2009 influenza A (H1N1) infection, including
both hospitalized patients and outpatients, were invited by the
Hong Kong Red Cross Blood Transfusion Service to give in-
formed consent for donation of their convalescent plasma vol-
untarily to treat patients with severe disease due to this novel
virus. All potential donors had the diagnosis of 2009 influenza
A (H1N1) infection confirmed by positive reverse transcription
polymerase chain reaction (RT-PCR) results for the influenza
A virus M and pandemic H1 genes and negative RT-PCR results
for the seasonal influenza A virus H1 and H3 genes in naso-
pharyngeal specimens. Clinical information for these potential
donors was retrieved from the hospital Computer Medical Sys-
tem, including baseline demographic data, date of symptoms
onset, date of the first positive virological test, presenting symp-
toms including fever, cough, sputum production and sore
throat, past medical and smoking history, the viral load from
nasopharyngeal specimens on diagnosis, detail of antiviral treat-
ment including oral oseltamivir and inhaled zanamivir, hos-
pitalization, radiological evidence of complication by pneu-
monia, laboratory results, and clinical outcome. All presenting
symptoms except fever were defined by patients’ report to stan-
dard questions asked by the clinicians. Fever was defined as a
single reading of the patient’s tympanic temperature of137.8C,
measured on presentation at the outpatient clinic or hospital.
Laboratory parameters in our analysis included blood lym-
phocyte count (standard range, to lympho-9 91.2 10 3.4 10
cytes/L), alanine transaminase level (standard range, 5–31 U/
L), lactate dehydrogenase level (standard range, 91–232 U/L),
and creatine kinase level (standard range, 26–192 U/L). Lab-
oratory parameters with values outside the standard range were
defined as abnormal. Donors who volunteered for a second
convalescent plasma donation had their paired convalescent
serum samples tested again for NAT before the second dona-
tion. The criteria for the diagnosis of pneumonia included fever,
cough or sputum, crepitations on auscultation of the chest, and
radiological finding of unexplained pulmonary infiltrate.
Nasopharyngeal specimens obtained on admission were sent
to the laboratory in viral transport medium. Total nucleic acid
extraction was performed using NucliSens easyMAG instru-
ment (bioMerieux), and RT-PCR was performed with modi-
fication, as described elsewhere [12, 13]. All procedures in-
volving clinical specimens and influenza virus were performed
in a biosafety level 2 laboratory with biosafety level 3 practices.
Serum samples from all potential donors were tested for NAT
by the microneutralization assay inside a type II Biosafety Cab-
inet in a Biosafety Containment level III facility. The 2009
influenza A (H1N1) virus strain A/HK/415742/09 (H1N1) was
used. The virus stocks were aliquoted and stored at 70C
until use. The 50% tissue culture infectious dose (TCID50) of
each virus was determined by titration in Madin Darby canine
kidney cells. One hundred TCID50 was used as inoculum in
100 mL of cell culture medium. The TCID50 of each stock virus
was calculated by the method of Reed and Muench. Serum
samples were 2-fold diluted in Eagle’s minimum essential me-
dium. Each 50-mL volume of virus inoculum was mixed with
equal volume of serum dilution (starting dilution of 1:10).
After a 2 h incubation at 37C in a 5% CO2 humidified atmo-
sphere, the mixture was added to the seeded microtiter plate.
The microtiter plates were seeded with a confluent layer of
Madin Darby canine kidney cells. Each flat-bottom 96-well
microtiter plate contained 12,500 cells per well, which was in-
cubated in a 5% CO2 atmosphere at 37C. After 1 h of infection,
virus-serum mixtures were removed, and Eagle’s minimum es-
sential medium with the addition of exogenous L-1-tosylamide-
2-phenylethyl chloromethyl ketone–treated trypsin (TPCK-
trypsin; Sigma Immunochemical) was added to each well. A
duplicate for each serum dilution was included on the same
microtiter plate. The cells were examined for cytopathic effect
at 72–96 h. The microneutralization titer is considered to be
the highest serum dilution at which the percentage of cytopathic
effect is 50%. All tests included a positive control of standard
serum, as well as a negative serum.
We used the Mann-Whitney U tests for comparison of the
median antibody level between the 2 groups of patients, with
previously defined presenting symptoms, baseline demographic
characteristics, smoking history, detail of antiviral treatment,
radiological evidence of complication by pneumonia, and lab-
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Figure 1. Distribution of serum neutralizing antibody titer of the 881
convalescent donors.
Table 1. Comparison of the Median Serum Neutralizing Antibody Level with Clinical and Laboratory
Parameters of the 881 Convalescent Donors
Variable or measurement
Patients with variable or
with abnormal result
Patients without variable or
with normal result
P
No (%)
of patients
Median antibody
level (range)
No (%)
of patients
Median antibody
level (range)
Antiviral treatment 575 (65.3) 80 (40–160) 306 (34.7) 80 (40–80) .64
Complication with pneumonia 19 (2.2) 160 (80–320) 862 (97.8) 80 (40–80) .003
Fever 793 (90) 80 (40–160) 88 (10) 80 (40–80) .66
Cough 722 (82) 80 (40–160) 159 (18) 80 (40–80) .37
Sputum production 108 (12.3) 80 (40–160) 773 (87.7) 80 (40–80) .005
Sore throat 531 (60.3) 80 (40–80) 350 (39.7) 80 (40–160) .29
Smoker 60 (6.8) 80 (40–160) 821 (93.2) 80 (40–80) .75
Lymphocyte count (n p 76) 37 (43.4) 80 (40–160) 39 (56.6) 80 (40–160) .583
ALT level (n p 76) 18 (23.7) 80 (40–160) 58 (76.3) 80 (70–200) .120
LDH level (n p 24) 13 (54.2) 80 (40–160) 11 (45.8) 80 (80–160) .494
CK level (n p 27) 6 (22.2) 120 (40–200) 21 (77.8) 80 (80–160) .887
Sex
Male 429 (49) 80 (40–160) … … .337
Female 452 (51) 80 (40–80) … …
Age, years
!20 76 (8.6) 80 (40–160) … … .34
20–29 437 (49.6) 80 (40–160) … …
30–39 187 (21.2) 80 (40–80) … …
40–49 132 (15) 80 (40–80) … …
50–55 49 (5.6) 40 (40–80) … …
NOTE. Lymphocyte count normal range, to lymphocytes/L; alanine transaminase (ALT) normal range,9 91.210 3.410
5–31 U/L; lactate dehydrogenase (LDH) normal range, 91–232 U/L; creatine kinase (CK) normal range, 26–192 U/L.
oratory results by univariate analysis. Factors that were signif-
icantly different statistically (as defined by P value !.05) in the
univariate analysis (except laboratory results with incomplete
sampling) were entered into the multivariate analysis by ordinal
regression, to determine independent factors associated with
high NAT. Correlation between nasopharyngeal viral load and
NAT was calculated by Spearman’s rank correlation coefficient
test. The aforementioned clinical factors were further assessed
by binary logistic regression to identify factors associated with
poor NAT response (!1:40). SPSS, version 16.0 for Windows
(SPSS), was used for statistical computation.
RESULTS
Four hundred twenty-nine of the 881 potential donors were
male, and the median age was 27 years (interquartile range
[IQR], 22–38 years). A Gaussian distribution of the NAT from
the donors was illustrated (Figure 1). All donors had their
convalescent NAT measured at day 21 or later after symptom
onset. A majority (67.4%) of the donors had the NAT measured
between days 21 and 42 after symptom onset (median, 35 days;
IQR, 29–46 days). The overall median NAT level was 1:80 (IQR,
1:40–1:80). Ninety percent of the 881 convalescent donors had
seroprotective titers of 1:40 or greater. The geometric mean
titers (GMTs) of donors with convalescent NAT measured be-
tween days 21 and 42 was 1:101.1 (95% confidence interval,
1:20–1:320). None of the donors had a history of underlying
medical illness. Sixty-five donors were hospitalized, of which
19 had a complication of pneumonia. All patients in our study
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Figure 2. Change of serum neutralizing antibody titer of 33 convales-
cent donors with paired samples. Closed squares, first neutralizing an-
tibody titers; open squares, second neutralizing antibody titers.
Table 2. Multivariate Analysis by Ordinal Regression of Pa-
rameters Independently Associated with High Serum Neutral-
izing Antibody Level
Variable
Odds ratio
(95% confidence interval) P
Complication with pneumonia 3.39 (1.49–7.61) .004
Sputum production 1.75 (1.01–3.01) .046
survived and recovered from the viral illness with no compli-
cations, such as respiratory failure or extrapulmonary spread.
A majority of the donors received antiviral treatment during
their infections (575 donors received oral oseltamivir 75 mg
twice daily for 5 days; none received inhaled zanamivir). Details
of the clinical and laboratory parameters of the 881 donors are
illustrated in Table 1. Thirty-three donors returned for consid-
eration of a second donation and had a paired convalescent
NAT measurement (Figure 2).
Univariate analysis showed that only complication by pneu-
monia and clinical presentation of sputum production were
associated with a higher level of NAT. Receipt of antiviral treat-
ment, sex, age, interval between presentation and blood taking
(Spearman correlation r, 0.02; ), and other parametersPp .59
were not associated with a lower level of NAT. Multivariate
analysis by ordinal regression showed that complication of
pneumonia (odds ratio, 3.39; 95% confidence interval, 1.49–
7.61; ) and sputum production (odds ratio, 1.75; 95%Pp .004
confidence interval, 1.01–3.01; ) were independentPp .046
factors for a higher level of NAT (Table 2). Binary logistic
regression demonstrated that being afebrile on influenza pre-
sentation was the only factor associated with subsequent failure
to achieve a protective NAT1:40 ( ) (data not shown).Pp .04
Eighty-seven donors had their initial nasopharyngeal speci-
men viral load determined at the time of diagnosis (Figure 3).
All nasopharyngeal specimens were obtained within 7 days after
onset of symptoms. The median viral load was copies/54.3 10
mL (IQR, to copies/mL). There is a statis-4 77 10 1.02 10
tically significant positive correlation between the nasopharyn-
geal specimen viral load and the NAT (Spearman correlation
r, 0.238; ), demonstrating that a high initial viral loadPp .026
was associated with a high NAT. However, nasopharyngeal viral
load did not show any correlation with pneumonia (Spearman
correlation r, 0.056; ) or sputum production (SpearmanPp .61
correlation r, 0.087; ).Pp .42
Thirty-three donors who had second convalescent serum
samples obtained for consideration of a second donation and
therefore had paired NAT measured (Figure 2). The median
time interval between the paired NAT measurements was 32
days (IQR, 17–42 days). None of the donors had a change in
NAT of 12 fold for the paired NAT tests. Thirteen donors
(39.4%) had static paired NAT measurements, 10 donors
(30.3%) had a 2-fold increase in NAT between measurements,
and 10 donors (30.3%) had a 2-fold decrease in NAT between
paired measurements. No recurrence or reinfection was doc-
umented in this case series.
DISCUSSION
This is the first study, to our knowledge, that has comprehen-
sively investigated the relationship of the NAT after 2009 in-
fluenza A (H1N1) infection with other clinical parameters in
a young and healthy population. This group of donors is un-
likely to have been exposed to 2009 influenza A (H1N1) in-
fection before, as opposed to people born before 1957 [10]. As
expected, the NAT assumed a Gaussian distribution slightly
skewed to the left, with most donors having a NAT of 1:40
and 1:80. There was also no significant difference in the NAT
across the different age groups. Only 2 factors were indepen-
dently associated with high NAT: the complication of pneu-
monia and clinical presentation of sputum production. Though
we cannot measure the viral load in bronchoalveolar lavage
specimens, both factors indicated lower respiratory tract in-
volvement and, therefore, more severe disease, resulting in a
more prominent immune response and a higher NAT.
Viral load reflects the dynamic interaction between viral rep-
lication and clearance by body defense mechanisms. In this
study, we also demonstrated a positive correlation between the
initial 2009 influenza A (H1N1) viral load and NAT. It is likely
that exposure of the immune system to a higher dose of antigen
and the associated higher viral load would result in a higher
NAT. Nevertheless, a high viral load does not necessarily mean
a more severe infection because the cytokine response of each
individual to the viral infection differs, leading to a variable
spectrum of clinical presentation. To our surprise, antiviral
treatment that suppressed the initial viral load and attenuated
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Figure 3. Correlation of viral load with serum neutralizing antibody titer
of 87 convalescent donors. Spearman correlation r, 0.238; .Pp .026
the clinical severity was not associated with a lower NAT, as
suggested in textbooks for some of the viral infections [14]. It
was believed that antiviral agents might blunt host immune
responses by altering humoral and cellular immune responses
indirectly through reductions in the dose of viral antigen ex-
posure, resulting in a subsequent lower NAT. However, it is
important to note that many viral respiratory diseases, such as
influenza A and respiratory syncytial virus infection, are as-
sociated with the early peaking of the viral load, which leaves
a narrow window of opportunity for antiviral treatment. In
both human influenza A and respiratory syncytial virus infec-
tion, the viral loads peaked at 2–3 days after symptom onset
in natural and experimental infections of healthy adults [15].
The early control of viral load in influenza A may be explained
by the onset of innate immune response and the early recruit-
ment of viral nucleoprotein specific cytotoxic T lymphocyte
response, which will start to clear virus infected cells because
of previous antigenic exposure to the influenza A viral matrix
1 and nucleoprotein, which are highly conserved for all subtypes
and strains. The apparent lack of effect of antiviral therapy may
be further confounded by the interval between the commence-
ment of oseltamivir treatment and the rapidity of oseltamivir
in the suppression of viral load. However, at least in this study
and in the mouse model [16], there was no evidence that receipt
of antiviral treatment would affect the subsequent humoral
immune response of the individual to the viral infection, and
it is therefore unlikely to be associated with a higher rate of
recurrence or reinfection.
From the test result of donors with paired convalescent NAT
measurements, most donors (70%) are able to sustain the NAT
level over a period of 1–4 months. Thirty percent of the donors
had a 2-fold increase in the NAT. This may represent an ac-
ceptable dilution error, rather than a reinfection. Similarly, the
remaining 30% donors had a 2-fold decrease in the NAT but
still maintained a NAT level of 1:40. This again may be a result
of dilution difference and may not represent an actual decrease
of the NAT. A number of donors demonstrated that they were
able to maintain a high NAT of 1:160, even after a period of
1100 days after symptom onset.
The NAT profile against influenza virus after natural infec-
tion has not been clearly reported in the literature, mainly
because of the confounding effect of crossreactivity between
different seasonal influenza virus strains. There were little data
on convalescent 2009 influenza A (H1N1), but in the recent
months, 3 randomized clinical trials [6–8] were performed to
assess the safety and immunogenicity of the monovalent, in-
activated, split-virus H1N1 2009 vaccine in adults. In all 3
clinical trials, a majority (95%) of the subjects aged 18–50
years achieved a seroprotection hemagglutination-inhibition ti-
ter of at least 1:40 by day 21 after administration of a single
15-mg nonadjuvanted vaccine or a 7.5-mg MF59-adjuvanted
vaccine. A similar result was achieved by microneutralization
antibody testing. This is comparable to the seroprotection rate
of 90% of the convalescent donors recovered from natural in-
fection by day 35 (median day from symptom onset) in our
study. However, the GMT achieved by vaccination with a single
15-mg nonadjuvanted vaccine ranged from 237.8 to 1:277.3
(hemagglutination inhibition) and 1:651.6 (microneutraliza-
tion) by day 21 after vaccination. A similar GMT (1:288.7) was
achieved with the 7.5-mg MF59-adjuvanted vaccine. By day 35
and 42 after vaccination, the GMT reached 1:212.9 and 1:321.3
with the nonadjuvanted and adjuvanted vaccines, respectively.
This level of GMT is much higher, compared with the GMT
of 1:101.1 achieved by natural infection in our study. Previous
studies on inactivated influenza vaccines in healthy adults and
young children have suggested that the seroprotection rate
could decrease by 30%–60% by 6 months after vaccination
[17–19]. This relatively low level of GMT achieved by natural
infection raised a concern that a significant proportion of the
patients who have recovered from the 2009 influenza A (H1N1)
infection in the summer of 2009 may experience a second attack
as their NAT falls below the 1:40 seroprotection level, unless
they receive the 2009 influenza A (H1N1) vaccine.
One limitation of the present study is its retrospective nature
and that it relies on the good will of patients to return and
provide a blood sample. Also, the nasopharyngeal and serum
samples for viral load and other laboratory investigations were
incomplete for all 881 donors. The number of paired titer
measurements was limited to 33 donors who returned for a
second convalescent donation. The strength of this study was
that a majority (67.4%) of the donors had their NAT measured
within 42 days after symptom onset, allowing comparison with
the antibody response after vaccination. Correlation between
NAT, initial viral load, and treatment with antivirals to the
subsequent NAT was also analyzed in this study.
In conclusion, the 2009 influenza A (H1N1) antibody titers
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after natural infection were maintained at a sufficiently high
level to offer adequate seroprotection for the first few months.
However, apart from those patients recovered from severe viral
illness, the low GMT resulting from natural infection raised a
concern that a significant proportion of the patients may ex-
perience a second attack after their NAT decreases below the
1:40 seroprotection level. About 10% of these convalescent
patients with low NAT may still benefit from vaccination. The
NAT correlated well with the initial viral load and is indepen-
dently associated with the severity of the viral illness, including
complication by pneumonia. The findings provide both the
clinical and virological markers for potential donors of con-
valescent plasma with high serum NAT, which can be used to
produce hyperimmune intravenous immunoglobulin. This will
maximize the time effectiveness of the limited plasmaphoresis
capacity in most blood transfusion services [11] and, therefore,
allow the production of sufficient doses within a shorter period
of time for randomized treatment trials on severe cases during
a pandemic. Longer follow-up is necessary to determine the
endurance of the antibody level.
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